Your browser doesn't support javascript.
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.
Wu, Kai; Choi, Angela; Koch, Matthew; Elbashir, Sayda; Ma, LingZhi; Lee, Diana; Woods, Angela; Henry, Carole; Palandjian, Charis; Hill, Anna; Jani, Hardik; Quinones, Julian; Nunna, Naveen; O'Connell, Sarah; McDermott, Adrian B; Falcone, Samantha; Narayanan, Elisabeth; Colpitts, Tonya; Bennett, Hamilton; Corbett, Kizzmekia S; Seder, Robert; Graham, Barney S; Stewart-Jones, Guillaume B E; Carfi, Andrea; Edwards, Darin K.
  • Wu K; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA. Electronic address: kai.wu@modernatx.com.
  • Choi A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Koch M; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Elbashir S; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Ma L; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Lee D; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Woods A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Henry C; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Palandjian C; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Hill A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Jani H; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Quinones J; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Nunna N; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Falcone S; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Narayanan E; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Colpitts T; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Bennett H; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Seder R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr, Bethesda, MD 20814, USA.
  • Stewart-Jones GBE; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Carfi A; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA.
  • Edwards DK; Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA. Electronic address: darin.edwards@modernatx.com.
Vaccine ; 39(51): 7394-7400, 2021 12 17.
Article in English | MEDLINE | ID: covidwho-1655207
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 11 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article